SuperworthCDT Equity EPS CDT
Diluted earnings per share by quarter and over the last twelve months, from 2022.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$217.75
- Fiscal year 2024
- −$10785341.50
CDT Equity's twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$217.75.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2024 | −$10785341.50 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$217.75 | n/a | n/a | |
| Q1 FY26 | −$1390.00 | n/a | n/a | |
| Q3 FY25 | −$82250.00 | n/a | −$2612591.00 | |
| Q2 FY25 | −$273.50 | n/a | −$8090216.00 | |
| Q1 FY25 | −$917567.50 | n/a | −$8095409.00 | |
| Q4 FY24 | −$1612500.00 | n/a | −$10785341.50 | |
| Q3 FY24 | −$5559875.00 | −841% | n/a | |
| Q2 FY24 | −$5466.50 | n/a | n/a | |
| Q1 FY24 | −$3607500.00 | n/a | n/a | |
| Q3 FY23 | $750000.00 | n/a | n/a | |
| Q2 FY23 | −$1500000.00 | n/a | n/a | |
| Q1 FY23 | −$2250000.00 | n/a | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest CDT Equity's size, closest first, today.
| Company | EPS, 12 months |
|---|---|
| CDTCDT Equity | n/m |
| SBFMSunshine Biopharma | n/m |
| DCOYDecoy Therapeutics | n/m |
| JAGXJaguar Health | −$6051.75 |
| LABTLakewood-Amedex Biotherapeutics | n/m |
| NXTSNexentis Technologies | n/m |
| VBIOValion Bio | n/m |
| ARTLArtelo Biosciences | −$207.09 |
| LNAILunai Bioworks | n/m |
| GNPXGenprex | n/m |
| GOVXGeoVax Labs | n/m |
| Peer median | −$3129.42 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on CDT Equity
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.